Anesthetic Principles Test 1

• Anesthesia:

  • Defined as the complete or partial loss of sensation.

• General Anesthesia:

  • A reversible state of central nervous system (CNS) depression produced by specific anesthetic agents.

  • Characterized by a loss of consciousness, amnesia, loss of pain sensation (analgesia), and immobility.

• Local, Regional, and Topical Anesthesia Distinctions:

  • Local Anesthesia: Specifically targets small, circumscribed anatomical areas.

  • Regional Anesthesia: Affects larger nerve distribution areas, most frequently accomplished using nerve blocks.

  • Topical Anesthesia: Anesthesia applied directly to, and limited in effect to, the skin and superficial subcutaneous tissues.

• Neuroleptanalgesia:

  • A state that is distinct from true general anesthesia.

  • Defined as a profound state of sedation and analgesia induced by the concurrent administration of an opioid and a tranquilizer.

• Anxiolytics, Sedatives, and Tranquilizers:

  • Anxiolytics: Any pharmacological agents that reduce anxiety; this broad classification includes both sedatives and tranquilizers.

  • Sedatives: Medications that reduce environmental awareness, cause CNS depression, and produce drowsiness; the patient remains only minimally aware of their surroundings.

  • Tranquilizers: Agents that induce a state of calm without producing overt drowsiness; the patient is unwilling to move, remains aware of the surroundings but is unconcerned, and can be roused from this state with appropriate stimulation.

• Anesthesia as a Continuum of Care:

  • Anesthesia cannot be viewed merely as an isolated, single surgical procedure.

  • Represents a continuous, multi-phase clinical process focused on managing patient safety, physiological stability, and comfort.

  • Extends across all procedural phases, literally beginning and ending at the patient's home.

• Assessment and Examination Testing Framework:

  • Evaluation modalities for anesthetic principles include: Multiple choice, True/False, Select the best word to complete the sentence, and Matching exercises (definitions, drug categories, etc.).

Anesthetic Safety, Planning Protocols, and Balanced Anesthesia

• Key Measures to Improve Anesthetic Safety:

  • Effective and clear client communication.

  • Comprehensive clinical staff training.

  • Aggressive, multi-tiered provision of analgesia.

  • Strategic administration of anxiolytics.

  • Implementation of low-stress, gentle patient handling techniques.

  • Integration of cognitive visual aids, including safety checklists, procedural algorithms, and informational tip boxes to enhance guideline usability and enable rapid data retrieval.

• Individualized versus Standardized Anesthetic Plans:

  • Universal Requirements: Both protocols must address every phase of anesthesia and incorporate comprehensive perioperative analgesia.

  • Individualized Plans:

    • Indications: Best utilized for higher-risk patients, animals assigned an American Society of Anesthesiologists (ASA) physical status of Class III and above, and non-routine surgical procedures.

    • Pros and Cons: Tailored directly to specific patient physiological derangements, but requires extensive planning and variable protocols.

  • Standardized Plans:

    • Indications: Best reserved for lower ASA classification categories undergoing routine, predictable elective procedures.

    • Pros and Cons: High degree of staff familiarity ensures team members know precisely what to anticipate; however, standardized plans lack flexibility for underlying pathological variations.

• Balanced Anesthesia:

  • The practice of combining multiple pharmacological agents in lower individual doses to optimize patient safety and clinical efficacy.

  • Requires a detailed working knowledge of individual drugs and their anticipated physiological effects.

  • Demands continuous, real-time monitoring of vital signs and depth indicators.

  • Requires ongoing adjustments of anesthetic drug combinations based on dynamically evolving patient needs.

  • Relies upon proactive preparedness and prevention strategies to minimize clinical morbidity and mortality.

The Four Phases of Anesthesia

• Phase 1: Preanesthesia:

  • Involves patient evaluation, risk assessment, drug protocol selection, equipment preparation, and clinical setup.

• Phase 2: Induction:

  • The transition phase taking a patient from a conscious state to unconsciousness.

• Phase 3: Maintenance:

  • The sustained period of surgical anesthesia during which procedural interventions occur.

• Phase 4: Recovery:

  • The transition phase from surgical unconsciousness back to full consciousness, normal reflexes, and sternal recumbency.

Preanesthetic Patient Evaluation, Diagnostics, and Risk Classification

• Core Components of the Preanesthetic Patient Evaluation:

  • Thorough review of complete patient history.

  • Hands-on physical examination.

  • Assessment of baseline diagnostic laboratory tests.

  • Evaluation of individual patient factors: age, breed conformation, body size, and behavioral temperament.

• Admission History Requirements:

  • Presence of any concurrent medical illness.

  • Administration of concurrent medications or supplements.

  • Prior history of anesthetic procedures and any documented adverse reactions.

  • Accurate fasting history (food and water access).

  • Direct confirmation of the scheduled surgical or diagnostic procedure.

• Recommended Preanesthetic Diagnostic Screening:

  • Packed Cell Volume (PCV) and Total Protein (TP).

  • Complete Blood Count (CBC).

  • Serum blood chemistry profiles.

  • Urinalysis.

  • Radiographs and other diagnostic imaging modalities.

  • Electrocardiogram (ECG).

• Essential Elements of Anesthetic Release Forms:

  • Legally documented informed consent.

  • Emergency contact telephone numbers.

  • Itemized written cost estimate.

  • Patient resuscitation status, distinguishing Advanced Life Support (ALS) from Basic Life Support (BLS).

• American Society of Anesthesiologists (ASA) Patient Risk Classifications:

  • Class I (C1): Minimum risk; normal, healthy patient presenting for elective procedures.

  • Class II (C2): Slight risk; patient with mild systemic disease, neonates, or geriatrics.

  • Class III (C3): Moderate risk; patient with severe systemic disease that limits activity but is not incapacitating.

  • Class IV (C4): High risk; patient with incapacitating systemic disease that is a constant threat to life.

  • Class V (C5): Grave risk; moribund patient not expected to survive $24\,\text{hours}$ with or without surgical intervention.

Fasting Guidelines and Preanesthetic Medication Principles

• Standard Preanesthetic Fasting Protocols:

  • Food Restriction: Food is typically withheld for a duration of $4\text{--}6\,\text{hours}$ and up to $12\,\text{hours}$ prior to general anesthesia.

  • Water Access: Water should remain accessible until premedication is administered; prolonged water withholding results in systemic dehydration.

  • Exceptions to Standard Fasting: Strict fasting exceptions apply to neonates, birds, rabbits, laboratory animal species, adult patients weighing $< 2\,\text{kg}$, and diabetic patients.

• Goals and Therapeutic Benefits of Pre-anesthetic Drugs:

  • Calm or sedate the patient, mitigating Fear, Anxiety, and Stress (FAS).

  • Provide drug synergy through multi-class interactions, which reduces the total dose of anesthetic agents needed to induce and maintain general anesthesia.

  • Counteract undesirable, negative side effects produced by other primary anesthetic agents.

Pharmacology of Preanesthetic Drug Classes

• Opioids:

  • Mechanism of Action: Bind to specific opioid receptors within the central nervous system to block ascending pain pathways.

  • Contraindications and Cautions: Exercise caution in patients with head trauma, pre-existing respiratory depression, or pronounced bradycardia.

  • Representative Drugs: Morphine, Fentanyl, Butorphanol, Methadone.

• Alpha-2 Adrenergic Agonists:

  • Mechanism of Action: Stimulate central alpha-2 adrenergic receptors, leading to decreased norepinephrine release; provides profound sedation, visceral analgesia, and skeletal muscle relaxation.

  • Contraindications and Cautions: Avoid or exercise extreme caution in patients with cardiovascular disease, hepatic dysfunction, or in pediatric and geriatric patients; frequently causes emesis.

  • Reversibility: Readily reversible using specific antagonists (e.g., antisedan / atipamezole).

  • Representative Drugs: Dexmedetomidline, Xylazine.

• Benzodiazepines:

  • Mechanism of Action: Enhance the inhibitory activity of gamma-aminobutyric acid (GABA) receptors, producing anxiolysis, skeletal muscle relaxation, and potent anticonvulsant effects.

  • Contraindications and Cautions: Avoid administration in animals with compromised liver function; can provoke paradoxical excitement and agitation in healthy, young animals.

  • Representative Drugs: Diazepam, Midazolam.

• Phenothiazines:

  • Mechanism of Action: Antagonize central dopamine receptors to induce tranquilization and provide antiemetic effects.

  • Contraindications and Cautions: Do not administer to animals that are hypotensive, prone to seizures, suffering from liver dysfunction, or geriatric; often causes visible prolapse of the third eyelid (nictitating membrane).

  • Representative Drugs: Acepromazine.

• Dissociatives (Cyclohexamines):

  • Mechanism of Action: Antagonize N-methyl-D-aspartate (NMDA) receptors; produce a unique state of dissociative anesthesia accompanied by somatic analgesia.

  • Clinical Applications: Used for induction, sub-anesthetic analgesic infusions, and as components of multimodal protocols.

  • Contraindications and Cautions: Contraindicated in patients with active head trauma, seizure disorders, or pre-existing cardiac disease.

  • Representative Drugs: Ketamine.

• Neurosteroids:

  • Mechanism of Action: Positive allosteric modulation of $GABA_A$ receptors.

  • Clinical Applications: Induces sedation when given intramuscularly (IM) and general anesthesia when given intravenously (IV) in small animals; highly convenient via IM route for fractious feline patients.

  • Contraindications and Cautions: Administer large IM volumes cautiously; carries a significant risk of respiratory depression if administered rapidly.

  • Representative Drugs: Alfaxalone.

• Anxiolytics / Pre-Visit Pharmaceuticals (PVP):

  • Mechanism of Action: Modulate synaptic neurotransmitter release, specifically altering GABA and serotonin pathways.

  • Clinical Applications: Mitigate Fear, Anxiety, and Stress (FAS) and promote pre-visit calming prior to clinical arrival.

  • Contraindications and Cautions: Sedative effects may become excessive in debilitated patients; patients must be monitored for gastrointestinal upset.

  • Representative Drugs: Gabapentin, Trazodone.

Comparative Profiles of Opioid Analgesics

• Fentanyl:

  • Level of Pain Control: Most profound analgesia among routine opioids.

  • Duration of Action: $20\text{--}30\,\text{minutes}$.

  • Receptor Activity and Use: Extremely potent full $\mu$/$\kappa$ agonist; administered as an IV bolus, Constant Rate Infusion (CRI), or transdermal patch.

  • Adverse Effects: Severe respiratory depression, pronounced bradycardia.

• Morphine:

  • Level of Pain Control: Profound analgesia.

  • Duration of Action: $2\text{--}4\,\text{hours}$.

  • Receptor Activity and Use: Full agonist; co-administered with tranquilizers. Often induces vomiting following IM injection; triggers systemic histamine release when administered rapidly IV.

  • Adverse Effects: Vomiting, histamine release (causing hypotension), bradycardia.

• Hydromorphone:

  • Level of Pain Control: Profound analgesia.

  • Duration of Action: $2\text{--}4\,\text{hours}$.

  • Receptor Activity and Use: Potent full agonist clinically similar to morphine; does not induce histamine release.

  • Adverse Effects: Postoperative hyperthermia in feline patients, sedation.

• Methadone:

  • Level of Pain Control: Profound analgesia.

  • Duration of Action: $2\text{--}4\,\text{hours}$.

  • Receptor Activity and Use: Full $\mu$ agonist with additional NMDA-receptor antagonist properties; induces significantly less emesis than morphine.

  • Adverse Effects: Sedation, respiratory depression.

• Buprenorphine:

  • Level of Pain Control: Moderate analgesia.

  • Duration of Action: $4\text{--}8\,\text{hours}$.

  • Receptor Activity and Use: Partial $\mu$ agonist characterized by high receptor affinity and slow onset; provides minimal sedation and is exceptionally well-suited for cats.

  • Adverse Effects: Mild sedation, respiratory depression.

• Butorphanol:

  • Level of Pain Control: Mild to moderate visceral analgesia.

  • Duration of Action: $20\text{--}90\,\text{minutes}$.

  • Receptor Activity and Use: $\kappa$ receptor agonist and $\mu$ receptor antagonist; serves as an effective sedative when combined with a tranquilizer.

  • Adverse Effects: Mild sedation, strictly limited duration and depth of somatic analgesia.

Role of Anticholinergics and Drug Interactions

• Reasons for the Clinical Decline of Routine Anticholinergic Premedication:

  • Anticholinergic agents wear off before induction begins.

  • Fail to show improvements in overall clinical outcomes.

  • Produce harmful physiological side effects depending on the nature of the surgery.

  • Are less effective at reducing inhalant maintenance gas requirements compared to delivering high-quality analgesia.

  • Pathophysiological effects documented in review: decreased HR, RR, constricted pupils, increased respiratory secretions, and increased peristalsis.

  • Mid-anesthetic Utility: Retain substantial value when used mid-anesthesia to reverse vagal bradycardia, provided that any previously administered alpha-2 agonist has been fully reversed or was not given.

• Contraindication: Concurrent Anticholinergics and Alpha-2 Adrenergic Agonists:

  • Mechanism of Incompatibility: Both drug classes ultimately allow unopposed sympathetic stimulation, forcing opposing physiological pathways to compete.

  • Vascular Consequences: Causes extreme peripheral vasoconstriction, driving blood pressure to excessively hypertensive ranges ($150\text{--}160\,\text{mmHg}$ systolic) with high risks of target organ damage.

  • Cardiac Consequences: Markedly escalates myocardial oxygen demand to dangerous levels.

  • Risk Stratification: Patients with occult, undiagnosed cardiac pathology face high risks of acute decompensation and fatal dysrhythmias.

Induction Principles, Preoxygenation, and Titration

• The Clinical Role of Induction Agents:

  • Pharmacologically transition a patient from consciousness to unconsciousness, achieving amnesia, muscle relaxation, and analgesia.

  • Most commonly administered via intravenous (IV) injection; can occasionally be performed via inhalation.

• Physiological Benefits of Preoxygenation:

  • Administration of $100\%$ oxygen for a duration of $3\,\text{minutes}$ achieves maximal hemoglobin saturation that persists for approximately $\sim 6\,\text{minutes}$.

  • Critical for patients presenting with airway disease, respiratory distress, predicted difficult endotracheal intubations, or pregnancy (to preserve fetal oxygenation).

• The Principle of Dosing to Effect:

  • Procedure: The full calculated drug dose is drawn into the syringe, but only small aliquots (typically one-quarter to one-half of the volume) are injected slowly at short intervals.

  • End-Points: Injections cease the moment the patient exhibits relaxation of the jaw tone and loss of the laryngeal reflex, permitting smooth endotracheal intubation without administering excess drug.

  • Rationale: Rapid intravenous boluses of induction agents routinely trigger severe respiratory depression and apnea in dogs and cats.

  • Primary Offending Agents: Apneic episodes secondary to rapid bolus administration occur most frequently with thiopental, propofol, and alfaxalone.

Injectable Induction Drug Classes and Protocols

• Phenols (Propofol):

  • Pros: Demonstrates rapid onset of action and short duration of effect; easy to titrate to clinical effect; yields smooth induction and recovery phases; safe for repeated dosing in both canine and feline patients.

  • Cons: Causes dose-dependent cardiorespiratory depression following rapid boluses; completely lacks analgesic properties; contains an unpreserved lipid emulsion base that supports rapid bacterial proliferation once opened.

• Neurosteroids (Alfaxalone):

  • Pros: Fast onset of action, short duration, and facile titration; serves as a reliable non-IV alternative to propofol; can be given intramuscularly (IM) to chemically restrain fractious or small patients.

  • Cons: Induces dose-dependent cardiorespiratory depression with notable risks of post-injection apnea and hypotension; can provoke muscle twitching or excitement during induction or recovery phases.

• Dissociative Agents / Cyclohexamines (Ketamine):

  • Pros: Provides somatic analgesia; delivers chemical restraint for aggressive or fractious animals; can be administered without a co-induction agent if necessary.

  • Cons: Causes intense skeletal muscle rigidity; elevates seizure risks; induces tachyarrhythmias; produces catalepsy (patient remains rigid with open eyes and centralized pupils), increasing the incidence of emergence delirium and rough recoveries.

• DKT Formulation ("Kitty Magic"):

  • Composition: A mixture combining dexmedetomidine ($0.5\,\text{mg/mL}$), ketamine ($100\,\text{mg/mL}$), and butorphanol ($10\,\text{mg/mL}$).

  • Preparation: Mixed together in a single syringe at an equal volumetric ratio of $1:1:1$.

  • Pros: Highly effective for brief, elective surgical procedures (such as feline orchiectomy/neuter); frequently eliminates the need for supplemental inhalant anesthetics.

  • Cons: Classified as an extra-label/off-label drug protocol, despite widespread clinical use.

• Barbiturates (Thiopental and Phenobarbital):

  • Thiopental Characteristics:

    • Pros: Controlled substance; provides rapid induction for short procedures; controls refractory active seizures; dramatically lowers intracranial pressure.

    • Cons: Severe cardiovascular and respiratory depression; causes extensive, severe perivascular tissue necrosis upon extravasation; no longer commercially available in Canada or the United States.

  • Phenobarbital: Short-acting barbiturate formulation and the most commonly used in ongoing seizure management.

• Coadministration of Dissociatives with Benzodiazepines:

  • Dissociative agents are routinely combined with a benzodiazepine to counteract muscle rigidity, eliminate catalepsy, and smooth the overall anesthetic induction.

  • Administration Constraints: Diazepam (or Midazolam/Diazepam) must be administered IV and is the only injectable drug that can be safely mixed within the exact same syringe alongside ketamine.

Inhalation Anesthesia: Delivery, Mechanics, and Inhalant Pros and Cons

• Chamber and Mask Inhalant Inductions:

  • Pros: Allows anesthetic induction in patients that cannot be physically restrained safely or animals that cannot tolerate injectable drugs.

  • Cons: High patient stress; prolonged time course; extremely difficult to monitor vital parameters; regularly triggers a violent Stage II excitement phase; delays securing a patent airway; exposes clinical staff to waste anesthetic gases; produces environmental pollution.

• Maintenance with Anesthetic Inhalant Gases:

  • Pros: Rapid, straightforward titration of anesthetic depth; minimal internal drug metabolism (allowing longer, safer procedures); provides continuous oxygen supplementation through a patent endotracheal tube.

  • Cons: Requires expensive specialized machinery and maintenance costs; creates waste anesthetic gas risks and atmospheric pollution.

• Characteristics of an Ideal Anesthetic Gas:

  • Patient Safety: Free of organ toxicity, produces robust skeletal muscle relaxation, and supplies residual postoperative analgesia.

  • Controllability and Kinetics: Rapid induction and quick recovery; effortless depth adjustment; minimal body fat retention.

  • Economic Viability: Inexpensive liquid agent and low machinery acquisition/maintenance costs.

  • Operator Safety: Non-toxic to staff, chemically stable, non-flammable, and non-explosive.

• Mechanism of Inhalant Delivery via the Anesthetic Machine:

  • Liquid anesthetic agent is poured into the precision vaporizer, where it volatilizes into a gas state.

  • Vaporized anesthetic blends with carrier oxygen to form "fresh gas."

  • The vaporizer dial determines the exact volumetric percentage ($\%$) delivered to the breathing circuit.

  • Fresh gas enters the patient's respiratory tract via a mask, chamber, or endotracheal (ET) tube (the safest, most secure delivery route).

• Mechanism of Gas Uptake in the Animal Body:

  • Inhaled gas moves across pulmonary alveoli and dissolves into capillary blood.

  • Circulating blood transports the anesthetic agent to the central nervous system and peripheral tissues.

  • Gas diffuses between arterial blood and cerebral tissue across concentration gradients.

  • Because elimination occurs continuously back across the lungs, the agent must be continuously inhaled to sustain anesthesia.

Physicochemical Properties of Anesthetic Gases

• Vapour Pressure:

  • Definition: The measure of a liquid agent's tendency to evaporate into a gaseous state at ambient room temperature (20^\r\n\text{C}); high vapor pressure correlates with chemical volatility.

  • Ideal Value: Low vapor pressure; ensures the agent is less volatile, easier to control, and carries a reduced risk of accidentally delivering excessive concentrations.

• Solubility Coefficient (Blood:Gas Partition Coefficient):

  • Definition: The ratio indicating the ease with which an anesthetic gas dissolves into blood compared to its distribution in alveolar gas.

  • Ideal Value: Low solubility coefficient; low blood solubility permits alveolar partial pressures to rise quickly, resulting in dramatically faster inductions and rapid recoveries.

  • Theoretical Importance: Considered the most critical physical property in theoretical anesthesia because it directly dictates the velocity of induction and recovery.

• Minimum Alveolar Concentration (MAC):

  • Definition: The lowest concentration of vapor within the pulmonary alveoli at which $50\%$ of patients do not respond with motor movement to a standard noxious or painful stimulus; quantifies drug potency.

  • Ideal Value: Low MAC; lower values denote significantly higher anesthetic potency, meaning lesser volumetric quantities of gas are required to maintain surgical anesthesia.

Comparison of Inhalant Agents: Modern and Historical

• Isoflurane:

  • Clinical Use: The most ubiquitous inhalant gas utilized in general small animal veterinary practices.

  • Pros: Produces rapid inductions and recoveries; economical purchase price; low MAC (high potency); undergoes negligible liver metabolism ($< 0.2\%$); safe for patients with pre-existing cardiac, renal, or hepatic disease, as well as geriatric patients.

  • Cons: Induces pronounced, dose-dependent respiratory depression; emits a pungent, irritating odor; can cause emergence excitement during recovery; provides absolutely zero postoperative analgesia.

• Sevoflurane:

  • Clinical Use: The second most common agent; widely favored for avian, exotic, research, and referral surgical cases.

  • Pros: Ultra-low solubility produces faster induction, exceptionally swift recoveries, and immediate depth changes; causes slightly less respiratory tract depression; pleasant, non-pungent odor.

  • Cons: Highly expensive (costs $7\text{--}8\times$ more than isoflurane); possesses a higher MAC (lower potency); necessitates its own dedicated, calibrated precision vaporizer; undergoes slightly more hepatic biotransformation ($2\text{--}5\%$).

• Historical Inhalants and Major Drawbacks:

  • Halothane: Induces marked myocardial depression, severe dysrhythmias, reduced cardiac output, and systemic hypotension. Undergoes high hepatic metabolism ($20\%$), risking hepatotoxicity; presents occupational exposure hazards to personnel. Thymol preservative precipitates inside the vaporizer, requiring frequent servicing; currently unavailable in Canada.

  • Methoxyflurane: Triggers profound respiratory depression; displays high blood solubility, leading to exceptionally sluggish inductions and prolonged recoveries; metabolites cause renal and hepatic necrosis; expensive per milliliter.

  • Diethyl Ether: Extremely flammable and volatile, carrying dangerous risks of surgical suite explosions. Promotes post-anesthetic nausea/vomiting; linked to chronic liver disease and oncogenesis.

• Nitrous Oxide and Diffusion Hypoxia:

  • Mechanism: When nitrous oxide delivery is terminated, the gas rapidly leaves the bloodstream and floods into the pulmonary alveoli along its concentration gradient.

  • Pathophysiology: This influx of nitrous oxide dilutes and displaces alveolar oxygen, producing acute diffusion hypoxia.

  • Prevention: Patients must be maintained on $100\%$ oxygen for a minimum of $5\,\text{minutes}$ following the discontinuation of nitrous oxide.

Stages and Planes of Anesthesia

• Stage I: Voluntary Movement / Disorientation:

  • Occurs immediately prior to loss of consciousness.

  • Patient experiences spatial disorientation and diminished sensitivity to pain.

  • Protective reflexes, heart rate, and respiratory rate remain entirely normal.

• Stage II: Involuntary Movement / Excitement Stage:

  • Characterized by dysphoria, excitement, paddling, and vocalization; clinically, the goal is to bypass this stage rapidly.

  • Protective reflexes are present and frequently exaggerated; pupils dilate; vital parameters fluctuate erratically.

  • Frequently observed during gas chamber/mask inductions, excessively slow IV inductions, or during emergence from anesthesia.

• Stage III: Surgical Anesthesia:

  • The period of unconsciousness, characterized by progressive muscle relaxation, slower heart rate, and depressed respiratory rate; divided into four distinct planes:

    • Plane 1 (Light): Inadequate for surgery; active swallowing, brisk palpebral reflexes, and variable muscle tone.

    • Plane 2 (Medium / Surgical): The optimal plane for standard surgery; ventromedial eye rotation, relaxed jaw tone, loss of pedal/palpebral reflexes, and stable cardiovascular function.

    • Plane 3 (Deep): Excessively deep; central eye position, dilated pupils, profoundly depressed heart rate and respiration, absent reflexes.

    • Plane 4 (Overdose): Early moribund state; jerking respiration, flaccid muscle tone, circulatory collapse, rapidly impending cardiac arrest.

• Stage IV: Terminal / Moribund Stage:

  • Marked by complete respiratory arrest followed rapidly by circulatory collapse and death.

  • Demands immediate, aggressive cardiopulmonary resuscitation (CPR) and circulatory support for survival.

Patient Monitoring Principles and Physical Parameter Assessment

• Core Purpose of Monitoring:

  • Permits early identification, proactive prevention, and rapid mitigation of physiological derangements, directly reducing anesthetic morbidity and mortality.

• Optimal Monitoring Practices and Intervals:

  • Continuous Evaluation: Hands-on assessment by a dedicated anesthetist operating with full, undivided attention, complemented by mechanical monitors.

  • Intraoperative Frequency: Anesthetic parameters must be documented on the anesthesia record at an interval of every $5\,\text{minutes}$ minimum.

  • Postoperative Frequency: Following extubation, vital parameters must be recorded every $15\,\text{minutes}$ until the patient achieves normal physiological function and sternal recumbency.

• Assessment of Physical Vital Signs:

  • Heart Rate and Pulse: Assessed via arterial pulse palpation, thoracic auscultation with a stethoscope, electrocardiography (ECG), pulse oximetry, and blood pressure monitoring (Doppler or oscillometric).

  • Respiratory Rate: Assessed via observation of thoracic wall expansions, watching the movement of the reservoir bag, tactile confirmation of air currents at the nares, and capnography.

  • Body Temperature: Measured using digital rectal thermometers, axillary probes, or continuous esophageal temperature thermistors.

• Eye Position Dynamics:

  • Serves as a reliable indicator of depth under inhalant anesthesia.

  • Light Plane: Eye is oriented centrally.

  • Surgical Plane: The globe rotates ventromedially.

  • Excessively Deep Plane: Eye returns back to a central position, often with widely dilated pupils.

• Muscle Tone Assessment:

  • Evaluated by physical resistance to manipulation, distinct from automatic reflex arcs.

  • Jaw Tone: Assessed by opening the patient's mandibles; tight resistance indicates light depth, while loose, flaccid resistance indicates deep anesthesia.

  • Anal and Tail Tone: Assessed by anal sphincter tightness or passive resistance to tail manipulation.

  • Limb Tone: Evaluated by passive flexion and extension of the appendicular joints.

• Protective Reflexes:

  • Palpebral Reflex: Blink response evoked by tapping the medial or lateral canthus of the eye.

  • Pedal Reflex: Limb withdrawal triggered by pinching a toe web (small animals).

  • Swallowing / Laryngeal Reflex: Pharyngeal constriction indicating returning consciousness and recovery.

  • Corneal Reflex: Retraction of the globe or blink in response to touching the cornea (indicates severe depth when absent).

  • Auricular Reflex: Pinna twitch or ear flick elicited by touching inner pinna hairs (especially useful in cats).

Normal Physiological Ranges Under Anesthesia

• Heart Rate (HR):

  • Canine: $60\text{--}160\,\text{bpm}$.

  • Feline: $120\text{--}220\,\text{bpm}$.

  • Physiology: Heart rate is depressed by general anesthetics and opioids; alpha-2 agonists induce an expected, physiologically safe vasoconstrictive bradycardia.

• Respiratory Rate (RR):

  • Canine: $8\text{--}20\,\text{bpm}$.

  • Feline: $20\text{--}30\,\text{bpm}$.

  • Physiology: Severely blunted by general anesthetics, readily resulting in hypoventilation.

• Blood Pressure (BP):

  • Systolic: $100\text{--}160\,\text{mmHg}$.

  • Mean Arterial Pressure (MAP): $70\text{--}100\,\text{mmHg}$.

  • Physiology: Blood pressure decreases secondary to anesthetic-mediated vasodilation and myocardial depression.

• Oxygenation ($SpO_2$):

  • Normal Range: $98\text{--}100\%$ on $100\%$ oxygen.

  • Physiology: Values drop rapidly during hypoventilation, respiratory depression, or pulmonary atelectasis.

• Ventilation ($EtCO_2$):

  • Normal Range: $35\text{--}45\,\text{mmHg}$.

  • Physiology: End-tidal $CO_2$ climbs progressively as anesthetics depress central ventilatory drive, leading to respiratory acidosis.

• Body Temperature:

  • Target Threshold: Maintain above $37^\circ\text{C}$ / $98.6^\circ\text{F}$.

  • Physiology: Declines under anesthesia due to peripheral vasodilation, lack of muscular movement, and suppressed baseline metabolic heat generation.

• Tissue Perfusion:

  • Clinical Targets: Mucous membranes must remain bubble-gum pink; Capillary Refill Time (CRT) must be $< 2\,\text{seconds}$.

  • Physiology: Perfusion deteriorates if cardiac output falls or peripheral vascular tone collapses.

Anesthetic Monitoring Equipment and Diagnostic Modalities

• Pulse Oximeter:

  • Non-invasively measures the functional oxygen saturation of arterial hemoglobin ($SpO_2$) alongside pulse rate.

• Capnometer and Capnograph:

  • Non-invasively quantifies the End-Tidal Carbon Dioxide ($EtCO_2$) concentration in expired gas ($35\text{--}45\,\text{mmHg}$) and tracks respiratory rate.

  • Displays a real-time capnogram waveform to evaluate expiratory dynamics, airway patency, and respiratory quality.

• Central Venous Pressure (CVP):

  • Invasively assesses systemic venous return and right atrial filling pressures via a jugular catheter advanced into the cranial vena cava and connected to a water manometer.

  • Normal Value: $< 8\,\text{cmH}_2\text{O}$.

• Arterial Blood Gas Analysis:

  • Directly quantifies the partial pressures of arterial oxygen ($PaO_2$), arterial carbon dioxide ($PaCO_2$), and blood pH from an arterial blood sample.

• Doppler and Oscillometric Monitors:

  • Non-invasively measure indirect arterial blood pressure, yielding systolic, diastolic, and mean arterial values.

• Electrocardiogram (ECG):

  • Monitors cardiac electrical conduction, tracking heart rate and detecting dysrhythmias in real time.

Postoperative Recovery, Extubation, and Record Keeping

• Legal and Clinical Mandates for Record Keeping:

  • Legal Retention: Complete anesthetic logs must be retained for a minimum of $5\,\text{years}$.

  • Regulatory Purpose: Necessary for accreditation by veterinary regulatory bodies.

  • Clinical Purpose: Reduces human error, establishes legal proof of care, and demonstrates patient safety standards.

• Critical Nature of the Post-Anesthetic Recovery Window:

  • The vast majority of all veterinary anesthetic deaths occur during the first $3\,\text{hours}$ immediately following surgery.

  • Patients must have their physiological parameters recorded every $15\,\text{minutes}$ until normal and resting in sternal recumbency.

• Species-Specific Extubation Guidelines:

  • Canine: Deflate the cuff and extubate immediately once the patient demonstrates active, repeated swallowing.

  • Brachycephalic Breeds: Maintain the endotracheal tube in place as long as possible, only extubating when the patient actively rejects the tube.

  • Feline: Extubate at the very first purposeful motor movement (such as an ear flick, blink, or foot kick) before the swallowing reflex triggers, minimizing laryngospasm risks.

Management of Airway and Recovery Complications: Laryngospasm, Dyspnea, and Hypothermia

• Laryngospasm:

  • Definition: An exaggerated, prolonged reflex closure of the arytenoid cartilages at the laryngeal entrance, partially or completely obstructing airflow.

  • Prevention:

    • Apply topical Xylocaine spray $1\text{--}2\,\text{minutes}$ prior to intubation.

    • Apply sterile lubricating gel to the ET tube.

    • Use an illuminated laryngoscope, employ gentle technique, and avoid contact with the arytenoid cartilages.

    • Extubate before swallowing becomes hyperactive; recover the patient in sternal recumbency with the neck extended, head supported, and no external pressure on the trachea.

  • Management of Mild Cases: Assess vital signs and verify pink mucous membrane color; deliver blow-by oxygen; if stridor persists, extend the head and neck and gently pull the tongue rostrally.

  • Management of Severe / Prolonged Cases: Maintain induction agents and intubation equipment immediately at hand; if cyanosis or apnea develops, re-induce with an injectable agent and immediately re-intubate; intravenous dexamethasone may be administered to alleviate localized tissue inflammation.

• Brachycephalic Airway Considerations:

  • Pathology: Stenotic nares, elongated soft palate, hypoplastic (narrowed) trachea, and obesity restrict airflow, predisposing to acute upper airway obstruction (dyspnea).

  • Management: Follow the treatment and supportive protocols outlined for acute laryngospasm.

• Hypothermia Prevention and Thermal Burn Safety:

  • Therapeutic Modalities: Combine passive insulation (blankets) with active external heating sources (heated oat bags, circulating warm water blankets).

  • Hazards to Avoid: Never use electric heating pads or uninsulated heating discs, which cause severe thermal burns.

  • Overwarming Prevention: Discontinue active heating once body temperature reaches within $1^\circ\text{C}$ of normal to prevent rebound hyperthermia, continuing with passive insulation only.

Management of Stormy, Dysphoric, and Prolonged Recoveries

• Stormy and Dysphoric Recoveries:

  • Pain Considerations: Distinguish emergent delirium from pain; if pain is suspected, immediately administer analgesics.

  • Type 1 (Excitement / Hallucinations in Semi-Conscious Patients): Reduce all external stimulation; place the patient in a quiet, dark, heavily padded kennel; minimize physical touch.

  • Type 2 (Vocalization and Paddling in Unconscious Patients): Gently reassure the patient with calm vocalizations, light petting, and physical contact; administer intravenous diazepam or additional sedatives/anxiolytics.

• Prolonged Recoveries:

  • Underlying Etiologies: Severe hypothermia, idiosyncratic drug reactions, underlying renal or hepatic compromise, or relative drug overdose (high premedication doses combined with brief procedural duration).

  • Interventions: Provide physical stimulation, administer warm intravenous fluids, restore core body temperature, and administer specific pharmacological reversal agents.

• Fresh Gas:

  • The precise mixture of carrier oxygen and vaporized inhalant anesthetic that leaves the precision vaporizer to be delivered to the patient circuit.